Matrix metalloproteinases (MMPs) are zinc endometallopeptidases that are involved in the degradation and remodeling of connective tissues. This family of enzymes shows proteolytic activity towards virtually all of the constituents of the extracellular matrix. The members of this family, currently numbering 20, can be classified into four groups, which are the collagenases that cleave triple-helical interstitial collagen; the gelatinases that cleave denatured collagen, elastin, and type IV and V collagen; the stromelysins that mainly cleave proteoglycans; and the membrane-type MMPs that have a C-terminal transmembrane domain for anchoring to the cell membrane. The MMPs are involved in crucial physiological and physiopathological events, such as wound healing, nerve growth, angiogenesis, and pregnancy. In these physiological processes, MMP activity is tightly regulated. [1] [2] [3] [4] [5] However, excessive MMP synthesis and release can lead to connective tissue degradation and destruction, which occurs in tumor invasion, metastasis, 6) corneal ulceration, 7) arthritis disease, 8a) periodontal disease, 9) and multiple sclerosis. 10) For example, increased levels of fibroblast collagenase (MMP-1) and stromelysin-1 (MMP-3) have been observed in the cartilage and synovium of patients with rheumatoid arthritis and osteoarthritis, and are correlated with the severity of the disease. 8b) Therefore, MMPs inhibitors may have a potent therapeutic effect on various proteolytic diseases.
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8b) Therefore, MMPs inhibitors may have a potent therapeutic effect on various proteolytic diseases.
Many MMP inhibitors have been synthesized and developed. Several compounds are currently undergoing advanced clinical trials, such as batimastat (1), 11) marimastat (2), 12) trocade (3), 13) and AG3340 (4) 14) (Fig. 1 ). These inhibitors mimic the sequence of the substrate-cleavage site of MMPs and have hydroxamate as a zinc-chelating group (ZCG). This kind of design has been widely applied for other MMPs inhibitors.
Previously, we also developed a series of peptidyl hydroxamates as MMP-1 inhibitors (Fig. 2) , 15) our compounds mimicked the P 4 -P 1 substrate rather than the P 1 -P 1 Ј or P 1 -P 2 Ј sites in the above-mentioned MMP inhibitors (1)- (4) . Inhibitors that mimic the P n Ј site have been studied extensively but little is known about P n site-mimicking inhibitors like our compounds because of their only modest inhibitory potency (IC 50 values in the order of 10 Ϫ6 M for MMP-1). However, we thought that this type of inhibitor could show further improvement of its inhibitory activity, since hydroxamate 15) and phosphorous 16) have been examined as ZCGs. Design Beside hydroxamate and phosphorous, the ZCGs utilized most frequently are thiol or carboxylate. The free thiols are unstable to oxidation in air at neutral pH during preparation and storage. 17) To avoid the disadvantage, we selected a carboxylate, which was expected to be relatively stable and to show good pharmacokinetics, as the ZCG. Although the carboxylate is a weaker ZCG than the others for MMP-1, 5) we designed the 2,3-diaminopropionic acid derivative (6) to compensate for this weakness. The amino acid moiety was expected to chelate the active site zinc ion by both amino and carboxylate groups in a similar manner as the copper complex of amino acid ( Fig. 3 : in peptide chemistry, the complex is used to selectively protect the lysine residue). However, the 2,3-diaminopropionic acid derivative (6) showed no inhibitory activity against MMP-1. This unexpected result led us to perform molecular modeling of compound 6 after it was docked with MMP-1. No report of X-ray crystallographic studies have yet been reported on a complex between the P n site of mimicking inhibitors and MMP-1. There is only one report about X-ray crystallography between neutrophil collagenase (MMP-8) and Pro-Leu-Gly-NHOH 18) which also mimicked P n site of collagen cleavage site, but exhibited weaker MMP-1 inhibitory potency than 5a.
Design and Synthesis of Carboxylate Inhibitors for Matrix Metalloproteinases
15) However, the sequence homology of the catalytic domain is high between MMP-1 and MMP-8, so both threedimensional structures are very similar. Therefore, we generated a three-dimensional structured model of a MMP-1 : compound 6 complex based on the crystal structure of MMP-1 (PDB entry: 1CGL) and the structure of a complex between MMP-8 and Pro-Leu-Gly-NHOH (PDB entry: 1JAN) using InsightII/Discover Ver2.98 (Molecular Simulations Inc., San Diego, CA, U.S.A.) (The details of the procedure are described in the experimental section). Certainly, Pro-Leu-Gly-NHOH, well explored P n site-mimicking inhibitor, was fit into the MMP-1 active site and confirmed that the hydroxamate was bound in a bidentate manner to the active site zinc ion on this software. Before generation of MMP-1 : compound 6 complex, we checked binding feature of MMP-1 : compound 5a complex. Each amino acid residues were well accommodated to corresponding subsites in a manner similar to the case of Pro-Leu-Gly-NHOH. And N-terminal Bz-Gly-moiety was fit into a shallow hydrophobic pocket consisting of Phe185, Pro189, Ile191, and Gly192. Binding features observed in the model of the compound 6 docked with MMP-1 are represented in Fig. 4 with the interatomic distances for important polar interactions. As a result, the only carboxylate of compound 6 was coordinated with the active site zinc ion in a bidentate manner, while the amino group formed a hydrogen bond with Ala 182 and did not interact with the zinc ion. Comparison with the model of a potent initial inhibitor (5a) docked with MMP-1 showed that the hydrogen bond between the carbonyl at the leucine in compound 6 and Ala 184 in MMP-1 was completely absent. In the case of compound 6, loss of this hydrogen bond might decrease its affinity for MMP-1. This model could indicate that a hydrophobic pocket, consisting of the residues Leu 181, Val 215, and Tyr 240, is located in the vicinity of the Nterminal group of compound 6. It may be presumed that substitution at the amino group might create a new hydrophobic interaction with this pocket. This hypothesis prompted us to measure the MMP-1 inhibitory activity of intermediate (10a) and it is noteworthy that compound 10a showed potent MMP-1 inhibitory activity (the IC 50 value was 5.0 mM). Discovery of this novel binding mode led us to explore further N-substitutents with improved inhibitory potency. We prepared compounds with five different bond structures, that is, compounds with carbamate (12a-e), amide (13a-f), sulfonamide (14a-c), alkylamino (15a, b), and urea (16) bonds (Chart 1). In order to determine the smallest molecule exhibiting potent MMP-1 inhibitory activity, the peptide was truncated along the sequence from its N-terminal based on compound 10a. Furthermore, to assess the interaction between the S 1 pocket of the enzyme and the methyl group, a 2,3-diaminobutanoic acid derivative (22) was also designed.
Synthesis Preparation of the carboxylate compounds is summarized in Charts 1 and 2. The key intermediate 2,3-diaminopropionic acid (8) was prepared from Boc-Ser-OMe under Mitsunobu conditions 19) or from Boc-Asn-OMe with iodosobenzene diacetate. 20) Using N-ethyl NЈ-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC)/1-hydroxy- benzotriazol (HOBt) as the coupling reagent, a fully protected peptide (9a) was obtained from compound 7 and 8 after easy work-up. The original amino acid compound 6 was obtained by saponification of the ester in 9a, followed by treatment with 4 N hydrogen chloride in ethyl acetate (4 N HCl in EtOAc). Truncated compounds, 10b and 10c, were also prepared in the same manner as 10a. The amino group at the a position of the carboxylate provided a functional handle onto which various moieties were introduced, as follows. The Boc group in the fully protected compound 9a was removed using 4 N HCl in EtOAc. Then the residue was treated with various alkyloxycarbonyl chlorides (for 12a-e), acyl chlorides (for 13a-f), or alkylsulfonyl chlorides (for 14a-c) in the presence of Et 3 N, followed by saponification of the methyl ester. N-Alkylation of 11 was performed by reductive amination with benzaldehyde or 3-phenylpropionaldehyde, followed by saponification of the methyl ester to give 15a and 15b. The substituted ureido compound 16 was prepared as follows. Compound 11 was treated with 1,1Ј-carbonyldiimidazole (CDI)/Et 3 N, followed by reaction with benzylamine and then saponification to the carboxylate was accomplished under the same conditions described above.
For the preparation of compound 22, we initially examined the Mitsunobu reaction with Boc-Thr-OMe (17) to obtain the protected 2,3-diaminobutanoic acid (18), but a,b-unsaturated dehydro amino acid (19) was obtained as the sole product (Chart 2). In order to avoid dehydration, N 2 ,O-diprotected 2(S),3(S)-diaminobutanol (20) was prepared from Boc-Thr-OH according to the procedure described by Nakamura et al. 21) After condensation of 20 and tripeptide (7a)
by the EDC-HOBt condensation method, the tert-butyldimethylsilyl group was removed by treatment with 70% aqeous AcOH, followed by oxidation with pyridinium dichromate to give the a desired 2,3-diaminobutylic acid derivative (22).
Results and Discussion
The carbamate compounds, 10a and 12a-e, showed variable of MMP-1 inhibitory activity depending on the size of the substituent (Table 1 ). The ethyl-substituted compound 12a exhibited no inhibitory activity, but the compounds with bulkier groups, such as an iso-butyl group (12b), showed moderate inhibitory activity (an IC 50 of 29 mM). The compound with a tert-butyl group (10a) showed nearly equipotent inhibitory activity compared with the original hydroxamate (5a, IC 50 of 7.7 mM). Likewise, the aromatic ring compounds (12c, d) exhibited inhibitory activity for MMP-1 in the order of 10 Ϫ6 M. However, the bulkiest substituent of 2,2,2-trichloroethyl group (12e), caused a small decrease in activity. According to these results, the S 1 Ј pocket of MMP-1 seemed to be well occupied by tert-butyl or p-methoxybenzyl groups, while the ethyl group was too small. In order to verify the MMP-1 model, we assessed compound 10a was docked into MMP-1, and the binding features are shown in Figs. 5 and 6. Coordination of the carboxylate group on the inhibitor with the catalytic zinc atom was observed, and the hydrogen bond between the carbonyl at leucine and Ala 184 was regained. In MMP-1, the lateral wall of the S 1 Ј subsite mainly consists of three amino acids (Leu 181,Val 215, and Tyr 240) and the floor of the pocket is formed by an Arg 214 residue. The tert-butyl group was accommodated in this pocket, but did not fully occupy it. Since there was further space between the pocket floorboard and the tip of the tertbutyl group, additional elongation of the substituent at the tip of this group might lead to an additional hydrophobic interaction with the S 1 Ј subsite. Replacement of the carbamate group with an amide group led to a dramatic decrease of potency, and all the amide compounds (13a-f) had no inhibitory activity (0% at 10 Ϫ3 M). Also, inhibitory activity was not observed with alkylamino compounds (15a, b) . Probably, the substituents of the amino groups in amide or alkylamino compounds were not positioned in the S 1 Ј pocket. The difference of potency may be accounted for by the carbamate oxygen atom forming a hydrogen bond with the enzyme and this bond directing the hydrophobic substituent properly the S 1 Ј pocket, but a reasonable explanation of the difference was not obtained from our computerized docking study. The sulfonamide compounds (14a-c) showed significant inhibition like that observed with the carbamate compounds ( Table 2) . Although a small substituent methyl group (14a) did not generate any inhibitory potency, an aromatic ring substituent (14b, c) showed inhibitory activity as potent as that of carba- Compound 10a shown as a liquorice model, binds to the MMP-1 active site shown as a Connolly molecular surface of MMP-1. The MMP-1 surface color is ranked according to the electrostatic potential on the MMP-1 surface. As shown with a stacked color bar in the figure, the negative/positive electrostatic potential, the deeper it is colored red/blue. A pink sphere almost buried in the MM-1 surface is a zinc ion coordinated in the MMP-1 active site. The figure was generated by Insight II. mate compound 12c. As described for the carbamate and sulfonamide compounds, a benzyl substituent at the N a position promoted inhibition, so a ureido compound incorporating a benzyl group (16) was prepared. However, 16 only exhibited moderate inhibitory activity (IC 50 ϭ60 mM). Installation of the methyl group at the P 1 position (described as compound 22) did not cause a dramatic shift of potency compared with that of 10a (IC 50 ϭ5.0, 2.4 mM, respectively). This observation as supported by our computerized docking study, in which the installed methyl group was exposed to the solvent and not oriented towards the enzyme.
Comparison between the truncated peptides (10b, c) and the original peptide (10a) showed that loss of the Gly residue (10b) represented only caused a 3-fold decrease in inhibition of MMP-1 compared with 10a, but a shorter peptide with deletion of the Gly-Pro sequence (10c) showed complete loss of inhibitory activity (Table 3 ). Based on these results and the lack of activity of compound 6, it seems that both the Boc group and the pyrrolidine ring of proline could have a critical role in recognition of the enzyme. The benzoyl group also contributed to increasing the affinity for MMP-1.
For some of the carboxylate compounds that showed micromolar potencies against MMP-1 i.e., 10a, 12c, 14c, and 22, MMP-3 inhibitory activity was also measured (Table 4) . Although the carbamate compounds (10a, 12c, 22) showed about 25-fold less potency for inhibition of MMP-3 than MMP-1, 14c exhibited 10 mM potency for MMP-3 (only a 4-fold decrease in potency compared with its inhibition of MMP-1) and was 16-fold more potent than the original hydroxamate compound 5b. Comparison of these carboxylate compounds and 5b suggested that the P 1 Ј substituent was important for inhibition of MMP-3, with the sulfonamide structure being especially appropriate.
Conclusion
In summary, we have discovered non-hydroxamate MMP inhibitors with a carboxylate ZCG that show no decrease of inhibitory activity compared with the lead compounds 5. During construction of the carboxylate compounds, we generated a three-dimensional model of an MMP-1: compound 6 complex based on the crystal structure of MMP-1 and the complex of MMP-8 with an inhibitor (Pro-Leu-Gly-NHOH) using computerized docking. We found structurally new MMP inhibitors, such as carbamate compound (10a, 12c, 12d, 22) and sulfonamide compound (14b, c), which were effective against MMP-1 with IC 50 values in the order of 10 Ϫ6 M. Compound 10a showed that important features for the inhibitory potency were both the Boc group and the pyrrolidine ring of proline. With respect to MMP-3 inhibitory potency, compound 14c showed stronger inhibitory activity compared with the lead compounds 5.
Because hydroxamates are often unstable and there is a risk of chronic toxicity arising from metabolic degradation to hydroxylamine, our carboxylate compounds may be safe and have better pharmacokinetics. Further chemical and pharmacological evaluation of this series will be reported in due course and it is hoped that these potent MMPs inhibitors will aid in the treatment of various enzymatic diseases.
Experimental
Model Building The atomic coordinates of the crystal structure of MMP-1 and MMP-8 complexed with an inhibitor (Pro-Leu-Gly-NHOH) were retrieved from the RCSB Protein Data Bank 22) (PDB entries: 1CGL 23) and 1JAN, 24) respectively). To form the S 2 pocket of MMP-1, Asp186 residue was moved outside of the pocket in a similar manner to Gln165 of MMP-8. Thus, Pro-Leu-Gly-NHOH could be accommodated in the MMP-1 active site. Then the three-dimensional structure of compound 5a was con- structed based upon Pro-Leu-Gly-NHOH to check the binding feature and decide the three-dimensional structure of Bz-Gly-Pro-Leu-NH-CH moiety, which is common structure of compound 6. The Bz-Gly-moiety was initially constructed from standard values (bond length, bond angle, and torsion angle) followed by searching for a pocket that could accommodate an aromatic ring by altering all of the torsion angles except for the amide bond. As a result, we found that the aromatic ring of the Bz-Gly-moiety could fit into a hydrophobic pocket consisting of Phe185, Pro189, Ile191, and Gly192. Eventually, based upon the structure of 5a, three-dimensional structure of compound 6 was constructed. The amino acid moiety was also constructed utilizing standard values (bond length, bond angle, and torsion angle). For modeling of the amino acid moiety, two conformations were assessed based on Ca-Cb free rotation, which are described as conformers A and B in Fig.  7 . After docking of conformer B into MMP-1, strong electrostatic repulsion could be expected between both the carboxylate of the amino acid moiety and the Glu 219 residue, resulting in a failure of docking simulation. For this reason, we chose conformer A as the docking model and then carried out energy minimization using Discover (Ver 2.98, Molecular Simulations Inc., San Diego, CA, U.S.A.). Minimization was preformed by 300 steps of the steepest descent, followed by 3000 steps of the VA09A method to remove steric clashes. Chemistry Melting points were determined on a Yanagimoto melting point apparatus without correction. IR spectra were taken with a PERKIN ELMER PARAGON 1000 FT-IR spectrometer. 1 H-NMR was recorded on a JEOL FX90A or JEOL JMN-AL300 spectrometer, and chemical shifts are given in ppm (d) from tetramethylsilane (TMS), which was used as the internal standard. Mass spectra were obtained on a JEOL JMS 700 spectrometer by electrospray ionization (ESI) or fast atom bombardment (FAB) ionization techniques. Optical rotations were measured in a JASCO DIP-140 apparatus.
General Procedure for the Preparation of Compounds (9) EDC (1.1 eq of 7) was added to a mixture of 3-amino-2(S)-(tert-butyloxycarbonyl-amino)propionic acid methyl ester (8) (1.05 eq of 7), HOBt (1.05 eq of 7), compound 7, and N,N-dimethylformamide (DMF) (4-7% v/w) at Ϫ12°C. The mixture was stirred at Ϫ3°C for 6 h then 0°C for 15 h. The reaction mixture was evaporated employing a rotary evaporator and a vacuum pump. The residue was dissolved in EtOAc, washed with 1 N aq. HCl, sat. aq. NaCl, 10% aq. Na 2 CO 3 and sat. aq. NaCl successively, dried (MgSO 4 ), evaporated in vacuo to give a crude product, which was purified by silica gel column chromatography (eluent; CHCl 3 : MeOHϭ50 : 1) and precipitated from Et 2 O to give 9 as colorless powder. 4 (2H, m), 3.1-3.4 (2H, m), 3.4-3.8 (2H, m) 
General Procedure for the Preparation of Compounds (12)-(14)
Compound 9a was treated with cold 4 N HCl in EtOAc (4% v/w) for 0.5-1.5 h. The reaction mixture was evaporated in vacuo and the residue was precipitated from Et 2 O, which were collected by filtration, dried under reduced pressure to give hydrochloride salt (11) as quantitative yield. To a solution of 11 in DMF (4-7% v/w), Et 3 N (2 eq of 11) and appropriate acyl chloride or sulfonyl chloride (1.05-1.1 eq of 11) were added successively. The mixture was stirred at room temperature overnight. Then the reaction mixture was diluted with EtOAc, washed with sat. aq. NaCl, water, 10% aq. Na 2 CO 3 and sat. aq. NaCl successively, dried (MgSO 4 ) then evaporated in vacuo. The residue was dissolved in MeOH (7-10% v/w) and 2 N aq. NaOH (2 eq of acylated compound) was added at 0°C, then the mixture was stirred for 1-2 h. The reaction mixture was acidified by adding 1 N aq. HCl (pHϭ2-3), MeOH was removed by evaporation, extracted with EtOAc, dried (MgSO 4 ) and evaporated in vacuo. The residue was precipitated from Et 2 O and reprecipitated from appropriate solvent system to give 12-14.
3-(N a -Benzoyl-glycyl-prolyl-leucyl-amino)-2(S)-(ethyloxycarbonylamino)propionic Acid (12a, R 1 ϭEthyl): Yield: 62% (reprecipitated from THF-n-hexane 0 (12H, m) 1.4-1.9 (4H, m), 2.0-2.4 (4H, m),  3.25 (2H, m), 3.6-3.9 (4H, m), 3.9-4.3 (3H, m), 4.4-4.6 (2H, m) , 6 .51 (1H, m), 6.75 (1H, m), 7.04 (1H, m), 7.4-7.55 (3H, m), 7.62 (1H, m) 3-(N a a -Benzoyl-glycyl-prolyl-leucyl-amino)-2(S)-(benzylamino)propionic Acid (15a, R 4 ‫؍‬Benzyl) NaBH 4 (31 mg, 0.494 mmol) was added to a mixture of 11 (260 mg, 0.494 mmol), benzaldehyde (50 ml, 0.494 mmol) and MeOH (3 ml) at 0°C. After stirring for 16 h at room temperature, the reaction mixture was evaporated in vacuo, diluted with EtOAc, washed with water and sat. aq. NaCl, dried (MgSO 4 ), then evaporated in vacuo. The crude product was purified by silica gel column chromatography (eluent; CHCl 3 : MeOHϭ20 : 1) to give methyl ester of the title compound as a white waxen oil (257 mg, 90%). The methyl ester was saponified by the same method used for preparation of 12 and precipitated from EtOAc-Et 2 3-(N a a -Benzoyl-glycyl-prolyl-leucyl-amino)-2(S)-N -benzylureidopropionic Acid (16) To a mixture of 11 (260 mg, 0.5 mmol) , Et 3 N (70 ml, 0.5 mmol), and THF (10 ml), CDI (97 mg, 0.6 mmol) was added at 0°C, and the mixture was stirred at room temperature for 2 h. Then benzylamine (55 ml, 0.5 mmol) was added and stirred overnight at the same temperature. The reaction mixture was diluted with EtOAc and washed with 1 N aq. HCl, sat. aq. NaCl, 10% aq. NaHCO 3 , and sat. aq. NaCl successively, dried (MgSO 4 ), then evaporated in vacuo. The residue was purified by silica gel
